Ensuring Timely Access to Generics Act of 2025
- Bill Number
- S. 3014
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-10-16: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-04-30T22:27:33Z
AI-Generated Summary
Purpose of the Legislation
The Ensuring Timely Access to Generics Act of 2025 aims to prevent delays in the approval of generic drugs by reforming the process for "citizen petitions." A citizen petition is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking it to take (or not take) specific actions related to drug approvals, such as reviewing safety or labeling. The bill targets petitions that might be used abusively to block generic competition, promoting faster access to affordable medications.
Key Provisions
- Requirements for Submitting Petitions:
- Individuals or companies must submit a citizen petition before filing any lawsuit against the FDA that seeks to delay, block, or challenge the approval of a generic drug application (under sections for abbreviated new drug applications or biosimilar products).
- Petitions and any supplements must be filed within 180 days after the submitter learns the key information supporting their request.
- Petitions must include all relevant information and arguments that would be used in a related lawsuit.
- FDA Review and Determination of Delaying Petitions:
- The FDA must decide within a set period (adjusted from 150 days in some cases) whether to approve, deny, or take other action on the petition.
- If the FDA finds a petition was submitted primarily to delay approval, it can prioritize or dismiss it. To make this determination, the FDA considers factors such as:
- Timeliness of submission relative to when the information was known.
- History of filing multiple or repetitive petitions.
- Submission close to a known approval date for a generic.
- Lack of supporting data, raising similar past issues, or requesting stricter standards than those applied to the original drug.
- The submitter's track record of delay-focused petitions.
- The FDA can issue guidance on additional factors.
- Handling of Lawsuits (Civil Actions):
- Courts must dismiss lawsuits against the FDA for non-compliance:
- Without prejudice (can be refiled) if no petition was submitted first (failure to exhaust administrative remedies).
- With prejudice (cannot be refiled) if the petition was untimely.
- Without prejudice if a lawsuit is filed before the FDA issues a final response on a timely petition.
- Exceptions are limited, removing prior allowances for certain urgent cases.
Significant Changes to Existing Law
- Amends Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which previously regulated citizen petitions but allowed more flexibility in timing and fewer dismissal mandates.
- Adds a new regulation reference (10.31) for petition procedures.
- Expands criteria for identifying delay-motivated petitions with a detailed list of factors, replacing vaguer language.
- Shortens or adjusts FDA response timelines (e.g., from a strict 150-day window to 151 days post-submission for certain approvals).
- Strengthens court dismissal rules, making it harder to bypass FDA review via lawsuits.
- Eliminates some prior exceptions that allowed petitions or actions outside standard processes and redesignates subsections for clarity.
Potential Impacts
- On Government Agencies: The FDA will face stricter timelines and more structured decision-making, potentially reducing backlog but increasing administrative burden for evaluating delay factors. It may issue new guidance to implement these rules.
- On Citizens: Patients and consumers could gain quicker access to lower-cost generic drugs and biosimilars, lowering healthcare costs and improving affordability.
- On Pharmaceutical Industry: Generic drug makers benefit from fewer delays, accelerating market entry. Brand-name drug companies (often petition filers) may face barriers to using petitions strategically, potentially reducing anti-competitive tactics.
- On International Relations: Minimal direct impact, though faster U.S. generic approvals could influence global drug pricing and trade in pharmaceuticals.
Main Stakeholders Affected
- FDA (as the Secretary of Health and Human Services): Primary enforcer, responsible for reviews, determinations, and guidance.
- Generic and Biosimilar Drug Manufacturers: Benefit from reduced barriers to approval.
- Brand-Name Drug Companies: Potentially limited in using petitions to protect market exclusivity.
- Patients and Consumers: Gain indirect benefits through faster, cheaper drug availability.
- Courts and Litigants: Handle fewer premature lawsuits, with clearer dismissal guidelines.
- Petition Submitters (e.g., advocacy groups, competitors): Must comply with tighter rules or risk petition invalidation.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the "exhaustion of administrative remedies" doctrine, requiring full FDA engagement before court involvement, which streamlines processes but may limit immediate judicial access. Courts gain explicit authority to dismiss cases, reducing frivolous litigation.
- Constitutional: Aligns with due process by providing structured petition timelines and FDA guidance, ensuring fair review without unduly restricting First Amendment rights to petition the government.
- Political: Bipartisan sponsorship (by Senators Shaheen and Collins) signals broad support for drug affordability. It addresses criticisms of the patent system and FDA processes delaying generics, potentially influencing future healthcare policy debates on competition and innovation. No major controversies noted in the bill text itself.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Collins, Susan M. [R-ME], Sen. Baldwin, Tammy [D-WI]
Recent Actions
- 2025-10-16: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-10-16: Introduced in Senate
Bill Versions
- Ensuring Timely Access to Generics Act of 2025 — issued 2025-10-16 — PDF (9 pages)